Thalidomide protects endothelial cells from doxorubicin‐induced apoptosis but alters cell morphology
- 1 February 2004
- journal article
- website
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 2 (2), 327-334
- https://doi.org/10.1046/j.1538-7933.2003.00573.x
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- A high rate of venous thromboembolism in a multi‐institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinomaCancer, 2002
- Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsBlood, 2002
- Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complicationsBlood Coagulation & Fibrinolysis, 2002
- Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid TumorsJournal of Clinical Oncology, 2002
- Doxorubicin Induces Apoptosis and CD95 Gene Expression in Human Primary Endothelial Cells through a p53-dependent MechanismPublished by Elsevier BV ,2002
- Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapyBlood, 2001
- Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosisEuropean Journal of Cell Biology, 2001
- Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyBlood, 2000
- Doxorubicin-induced Apoptosis in Endothelial Cells and Cardiomyocytes Is Ameliorated by Nitrone Spin Traps and EbselenPublished by Elsevier BV ,2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999